OncoMatch/Clinical Trials/NCT05487391
A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.
Is NCT05487391 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments for carcinoma, non-small-cell lung.
Treatment: QL1706 · Vinorelbine Tartrate · Paclitaxel · Cisplatin · Carboplatin · Pemetrexed — The purpose of this study is to evaluate the efficacy and safety of QL1706 combined with platinum-based chemotherapy versus placebo combined with platinum-based chemotherapy in adjuvant treatment of stage II-IIIB NSCLC without EGFR-sensitizing mutations and ALK fusions after complete surgical resection.The subjects were randomly divided into two groups according to 1:1, with about 316 subjects in the experimental group and the control group.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR wild-type
Non-squamous NSCLC subjects without EGFR-sensitizing mutation or ALK fusion gene.
Required: ALK wild-type
Non-squamous NSCLC subjects without EGFR-sensitizing mutation or ALK fusion gene.
Disease stage
Required: Stage II, IIIA, IIIB
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: neoadjuvant chemotherapy
Previous treatment with neoadjuvant/adjuvant chemotherapy
Cannot have received: adjuvant chemotherapy
Previous treatment with neoadjuvant/adjuvant chemotherapy
Cannot have received: immune checkpoint inhibitor
Previous treatment with ... immune checkpoint inhibitor therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05487391 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require EGFR?
Yes, EGFR wild-type is a required biomarker for enrollment.
Does this trial require ALK?
Yes, ALK wild-type is a required biomarker for enrollment.
What disease stage is eligible?
Stage II or IIIA or IIIB is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages